Terminal-Restriction Fragment Length Polymorphism (T-RFLP) Analysis for Changes in the Gut Microbiota Profiles of Indomethacin- and Rebamipide-Treated Mice

Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Digestion Jg. 86; H. 3; S. 250 - 257
Hauptverfasser: Imaeda, Hirotsugu, Fujimoto, Takehide, Takahashi, Kenichiro, Kasumi, Eiji, Fujiyama, Yoshihide, Andoh, Akira
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Basel, Switzerland S. Karger AG 01.01.2012
Schlagworte:
Alanine - analogs & derivatives
Alanine - toxicity
Animals
Bacteroides
Cecum - drug effects
Cecum - microbiology
Cecum - pathology
Clostridiaceae
Disease Models, Animal
DNA, Bacterial - genetics
Drug Therapy, Combination
Female
Gastrointestinal Tract - drug effects
Gastrointestinal Tract - microbiology
Gastrointestinal Tract - pathology
Ileum - drug effects
Ileum - microbiology
Ileum - pathology
Indomethacin - toxicity
Metagenome - genetics
Mice
Mice, Inbred C57BL
Original Paper
Polymorphism, Restriction Fragment Length
Prevotella
Quinolones - toxicity
Nonsteroidal anti-inflammatory drugs
Terminal-restriction fragment length polymorphism
16S ribosomal RNA
BslI digestion
ISSN:0012-2823, 1421-9867, 1421-9867
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background/Aims: We investigated the effects of indomethacin and rebamipide on the gut microbiota profiles using terminal restriction fragment polymorphism (T-RFLP) analysis. Materials and Methods: Female C57BL/6J mice were given indomethacin (10 mg/kg, s.c.) once a day and 2.5 mg rebamipide orally 3 times a day. After 7 days, they were sacrificed, and luminal contents were obtained from the ileum and cecum. The gut microbiota communities were analyzed by T-RFLP analysis with BslI digestion. Results: T-RFLP analyses showed that rebamipide and indomethacin had no significant effects on the gut microbiota profiles in the ileum and cecum. In contrast, the combination of rebamipide + indomethacin induced a significant change in the gut microbiota. The changes in the microbiota composition induced by the combination of rebamipide + indomethacin were characterized by the increase in the orders Bifidobacteriales and Lactobacillales, the genera Bacteroides and Prevotella and the family Clostridiaceae. The diversity of the gut microbiota community generated by the combination of rebamipide + indomethacin was significantly higher than those induced by either rebamipide or indomethacin alone. Conclusion: The combination of rebamipide + indomethacin induces remarkable changes in the gut microbiota composition and diversity. The clinical activity of rebamipide on nonsteroidal anti-inflammatory drug-induced intestinal injury may be exerted through a modulation of the gut microbiota.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:0012-2823
1421-9867
1421-9867
DOI:10.1159/000341508